Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Joint Stock Company «Biocad» has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The company's current prosecution is centralized with no fragmentation across examiners or units. This concentration in 1 distinct art unit and 1 distinct examiner means that the company's current intellectual property effort is centered on a single point of review at the USPTO.
KASAYAN, KATRIEL BARCELLANO is the busiest examiner for the company, holding 1 busiest examiner pending office action. This single action represents the entirety of the 1 pending office action currently active. As the only examiner involved, KASAYAN, KATRIEL BARCELLANO has complete oversight of the company's current filings in the Biotechnology & Pharmaceuticals field. This singular focus allows for a direct and uncomplicated relationship between the applicant and the examiner.
Practitioners should note that the outcome of the company's current prosecution depends entirely on the review of KASAYAN, KATRIEL BARCELLANO within the assigned 1 distinct art unit. There are no other 1 pending office action deadlines or other examiners to coordinate with at this time. This simplicity in the portfolio's distribution reduces the administrative burden but also means that the company's success is tied to a single individual's interpretation of the Biotechnology & Pharmaceuticals technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18689751 | INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON | KASAYAN, KATRIEL BARCELLANO | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18689751 | INDUCIBLE PROMOTER, VECTOR AND HOST CELL BASED THEREON | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJoint Stock Company «Biocad» has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Katriel Barcellano Kasayan has the most, with 1 of Joint Stock Company «Biocad»'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.